Future Journal of Pharmaceutical Sciences最新文献

{"title":"Application of the quality by design (QbD) approach to the development and validation of analytical methods for the quantification of Lumateperone Tosylate as the bulk drug and capsule dosage form by HPLC","authors":"Vasudha S. Bavadekar,&nbsp;Angha M. Joshi,&nbsp;Ujwala S. Desai","doi":"10.1186/s43094-025-00779-6","DOIUrl":"10.1186/s43094-025-00779-6","url":null,"abstract":"<div><h3>Background</h3><p>The current studies involve the development of a liquid chromatographic method that is highly effective (HPLC) for the Lumateperone Tosylate method that is simple, rapid, accurate, precise, and economical, all made possible by analytical quality by design (AQbD). The HPLC method’s experimental settings were multivariately optimised by using the design of experiments to determine critical method parameters, and the Ishikawa diagram was used for risk assessment. A two-factor, three-level design was used for the factor screening investigations. Mathematical models were created using two independent factors: the buffer’s pH and the composition of the mobile phase. The response surface methodology and the impacts of these independent aspects were thoroughly examined using central composite design, which allowed for the evaluation of the critical method attributes (CMAs). The parameters of method robustness include retention time, peak area, and symmetry factor. Utilising the desirability function, the optimisation of the CMAs took place at the same time.</p><h3>Results</h3><p>According to the contour diagram’s optimised data, 10 mM ammonium acetate buffer (pH = 3.2): acetonitrile (80:20 v/v) was selected as a mobile phase with a 1 mL/min flow rate. A Zorbax SB C18 250 × 4.6 mm, 5 μ chromatographic column with a UV detector at 230 nm was used and oven temperature was maintained at 25 °C. Lumateperone Tosylate showed linearity in the concentration range of 25–250 µg/mL (r² = 0.9921). % RSD for interday and intraday precision was found to be 0.25–0.52 and 0.12–0.32, respectively. The % assay of drug content was found to be 100.01 ± 0.06, and accuracy was found to be 100.30–100.65%. In compliance with ICH recommendations, the optimised assay conditions were validated.</p><h3>Conclusion</h3><p>Therefore, it was clearly shown from the results that the AQbD methodology could be effectively used to optimise the HPLC method for Lumateperone Tosylate analysis. The technique was used to assess the Lumateperone Tosylate content in capsules as well.</p></div>","PeriodicalId":577,"journal":{"name":"Future Journal of Pharmaceutical Sciences","volume":"11 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://fjps.springeropen.com/counter/pdf/10.1186/s43094-025-00779-6","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143489519","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Icariin zeinmersomes display enhanced anti-proliferative and pro-apoptotic activities in colon cancer cells","authors":"Mohammed Z. Nasrullah,&nbsp;Osama M. Ashour,&nbsp;Nabil A. Alhakamy,&nbsp;Lenah S. Binmahfouz,&nbsp;Rawan H. Hareeri,&nbsp;Faisal Alsenani,&nbsp;Hussam I. Kutbi,&nbsp;Ashraf B. Abdel-Naim","doi":"10.1186/s43094-025-00780-z","DOIUrl":"10.1186/s43094-025-00780-z","url":null,"abstract":"<div><h3>Background</h3><p>The present study aimed at investigating the effectiveness of zeinmersomes (ZMS)-based nano-formulation to enhance icariin (ICA) cytotoxicity in colon cancer cells. The prepared ICA-ZMS was characterized with respect to particle size, entrapment efficiency, and in vitro release.</p><h3>Results</h3><p>ICA-ZMS showed higher cytotoxicity in HCT-116 cells compared to HT-29 and Caco-2 cells with almost no cytotoxicity in normal HCoEpC colon cells. In this regard, ICA-ZMS exhibited potentiated cytotoxicity as compared to ICA-raw. In HCT-116 cells, ICA loaded on ZMS exhibited better cellular penetration compared to ICA-raw. The accumulation of HCT-116 in the S phase was identified using cell cycle analysis. Annexin V staining highlighted a potent pro-apoptotic activity of the prepared ICA-ZMS. This with confirmed by the observed up-regulated Bax and down-regulated Bcl-2 mRNA expression. Further, mRNA expression of p53, cytochrome C, and caspase-3 was significantly increased by exposing cells to ICA-ZMS. This was associated with a detectable decline in mitochondrial membrane potential. These data were confirmed by the ability of ICA-ZMS to significantly enhance the life span of Ehrlich ascites carcinoma-bearing mice.</p><h3>Conclusion</h3><p>This study suggests that the loading of ICA on ZMS nanoparticles enhances its cytotoxic and pro-apoptotic activities. This involves modulation of p53-dependent mitochondrial signaling.</p></div>","PeriodicalId":577,"journal":{"name":"Future Journal of Pharmaceutical Sciences","volume":"11 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://fjps.springeropen.com/counter/pdf/10.1186/s43094-025-00780-z","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143489605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quercetin inhibits steroid-induced hypergluconeogenesis in Saccharomyces cerevisiae","authors":"Victor Arokia Doss,&nbsp;Gowtham Subramaniam,&nbsp;Keerthana Manoharan","doi":"10.1186/s43094-025-00777-8","DOIUrl":"10.1186/s43094-025-00777-8","url":null,"abstract":"<div><h3>Background</h3><p>Steroid-induced hypergluconeogenesis is a significant contributor to hyperglycemia, often complicating the therapeutic use of steroids. This study investigates the potential of quercetin, a naturally occurring flavonoid, to mitigate steroid-induced hypergluconeogenesis in <i>Saccharomyces cerevisiae</i>. The levels of glucose, total proteins, free amino acids, pyruvate, lactate and antioxidants were assessed in the quercetin-treated yeast cells induced with betamethasone at different time intervals. The glucose uptake potential of yeast cells treated with quercetin was also studied and also the effect of steroids and quercetin on cell viability was analyzed.</p><h3>Results</h3><p>Our results show that quercetin effectively reduces gluconeogenesis by normalizing the levels of metabolites involved in the process and alleviates the hyperglycemic effects associated with steroid exposure. Quercetin-treated yeast cells also demonstrated a better uptake of glucose. Additionally, quercetin was found to improve the overall cell viability highlighting its role in modulating glucose metabolism.</p><h3>Conclusion</h3><p>These outcomes suggest that quercetin can serve as a promising adjunct therapy for managing steroid-induced metabolic disturbances, providing a natural and effective approach to counteracting steroid-induced hyperglycemia.</p></div>","PeriodicalId":577,"journal":{"name":"Future Journal of Pharmaceutical Sciences","volume":"11 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://fjps.springeropen.com/counter/pdf/10.1186/s43094-025-00777-8","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143455450","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stability indicating RP-UPLC determination of three antiviral agents: emtricitabine, tenofovir, and rilpivirine in combined pharmaceutical dosage form","authors":"Vinutha Kommineni,&nbsp;Spoorthi Pohar,&nbsp;N. Sri Lakshmi,&nbsp;N. Swarna Latha","doi":"10.1186/s43094-025-00765-y","DOIUrl":"10.1186/s43094-025-00765-y","url":null,"abstract":"<div><h3>Background</h3><p>The concurrent measurement of emtricitabine, tenofovir, and rilpivirine was achieved using UPLC, employing Analytical Quality by Design (AQbD) principles, which encompass response surface methodology (RSM) and Box–Behnken design (BBD). This approach offers a systematic and efficient method for improving analytical procedures and ensuring reliable results.</p><h3>Results</h3><p>Analyte separation was accomplished using an Endoversil C 18 (2.1 × 50 mm, 1.7 µm) column as the stationary phase. The mobile phase consisted of a mixture of 80% orthophosphoric acid (0.1%) and 20% acetonitrile, with a flow rate of 0.4 ml/min and a column temperature of 30 °C. A photodiode array detector was used for detection at 270 nm. The peak area response-concentration curve exhibited linearity across ranges of 50–250 µg/ml (emtricitabine), 100–500 µg/ml (tenofovir), and 10–50 µg/ml (rilpivirine). Quantitation limits were determined to be 0.099 µg/ml (emtricitabine), 0.165 µg/ml (tenofovir), and 0.066 µg/ml (rilpivirine). The method was successfully validated for the simultaneous determination of emtricitabine, tenofovir, and rilpivirine in combined tablet dosage form. Percentage recoveries were 99.89%, 99.52%, and 100.20%, with relative standard deviations of 0.415%, 0.268%, and 0.559% for emtricitabine, tenofovir, and rilpivirine, respectively.</p><h3>Conclusion</h3><p>The performance of the proposed method was evaluated against reported RP-UPLC methods and found to be rapid and cost-effective. The developed and validated stability indicating RP-UPLC method proved suitable for quality control and drug analysis.</p></div>","PeriodicalId":577,"journal":{"name":"Future Journal of Pharmaceutical Sciences","volume":"11 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://fjps.springeropen.com/counter/pdf/10.1186/s43094-025-00765-y","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143431068","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lentinula edodes mycelia extract abrogates chemotherapy-evoked cold and mechanical allodynia in mice","authors":"Masanobu Tsubaki,&nbsp;Natsuki Kato,&nbsp;Keisuke Tateishi,&nbsp;Kengo Yoshida,&nbsp;Taira Matsuo,&nbsp;Rie Komori,&nbsp;Toshio Morikawa,&nbsp;Shozo Nishida","doi":"10.1186/s43094-025-00778-7","DOIUrl":"10.1186/s43094-025-00778-7","url":null,"abstract":"<div><h3>Background</h3><p>Chemotherapy-induced peripheral neuropathy (CIPN) is a detrimental outcome of various antineoplastic drugs, such as paclitaxel (PTX), vincristine (VCR), oxaliplatin (L-OHP), and bortezomib (BOR). CIPN results in pain and disability, thereby reducing quality of life and discontinuation of chemotherapy. Currently, the only effective treatment for CIPN is using duloxetine. Therefore, development of new treatments is necessary. Extract of <i>Lentinula edodes mycelia</i> (LEM) improves the quality of life for individuals undergoing chemotherapy treatment. As treatment with LEM may attenuate CIPN after chemotherapy, this study was conducted to determine whether treatment with LEM abrogates L-OHP-, PTX-, VCR-, and BOR-evoked cold and mechanical allodynia in mice.</p><h3>Results</h3><p>We found that LEM exhibits protective effects against cold and mechanical allodynia in mice treated with L-OHP, PTX, VCR, or BOR. We also found that the administration of L-OHP, PTX, VCR, and BOR elevated mRNA expression of Cav3.2, Cav3.3, and NR2A in the DRG of mice, whereas treatment with LEM abrogated L-OHP-, PTX-, VCR-, and BOR-induced Cav3.2 and NR2A mRNA expression. In addition, LEM treatment abrogated L-OHP-, PTX-, VCR-, and BOR-induced ERK1/2 phosphorylation in the DRG and spinal cord of mice. Furthermore, treatment with LEM reversed symptoms in mice that developed cold and mechanical allodynia after receiving L-OHP, PTX, VCR, or BOR.</p><h3>Conclusion</h3><p>These findings suggest that the attenuation of expression of phosphorylated ERK1/2, Cav3.2, and NR2A upon LEM treatment may be an effective prophylactic and therapeutic strategy against L-OHP-, PTX-, VCR-, and BOR-induced cold and mechanical allodynia.</p></div>","PeriodicalId":577,"journal":{"name":"Future Journal of Pharmaceutical Sciences","volume":"11 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://fjps.springeropen.com/counter/pdf/10.1186/s43094-025-00778-7","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143431023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antimicrobial and antioxidant potential of Yemeni Sidr honey against multidrug-resistant pathogens – in vitro and in silico studies","authors":"Hani A. Alhadrami,&nbsp;Ahmed M. Sayed,&nbsp;Hossam M. Hassan,&nbsp;Mostafa E. Rateb,&nbsp;Marwa A. Taher","doi":"10.1186/s43094-025-00774-x","DOIUrl":"10.1186/s43094-025-00774-x","url":null,"abstract":"<div><h3>Background</h3><p>Honey’s medical values have been extensively recorded in literature. Yemeni Sidr honey was reported to treat many ailments like stomach and respiratory disorders. ESKAPE and other multidrug-resistant pathogens are considered one of the top three risks to global public health, so alternative strategies become critical demand against such pathogens or their biofilms. The current study aimed to explore the antibacterial and antioxidant potential of the Yemeni Sidr honey extracts. The antibacterial activity of the two Yemeni Sidr honey extracts (ST and SM) was assessed against different pathogenic strains. The antioxidant activity was also evaluated using ORAC, ABST, 5-LOX, and DPPH. Furthermore, 2D HSQC data of both ST and SM honey extracts were collected uploaded to the SMART platform to identify the possible metabolites in these extracts. The identified metabolites were analyzed using docking and molecular dynamic simulations (MDS) to identify the key players in the antibacterial action.</p><h3>Results</h3><p>The antibacterial activity revealed that ST and SM extracts have similar activity against all tested pathogens<i>.</i> ST extract exhibited superior antibiofilm effect against <i>P. aeruginosa</i> and <i>C. albicans</i> by 68.2% and 62.6%, respectively, exceeding the reference standards. Moreover, ST extract displayed the highest antioxidant power against all assays except the DPPH assay. SMART dereplication of the HSQC data of ST extract revealed the annotations of five carbohydrates (fructose, glucose, mannose, maltose, and sucrose); while, SM extract showed three major phenolic compounds (chrysin, ellagic acid, and caffeic acid), in which chrysin and ellagic acid were likely the key players in the antibacterial action, based on MDS.</p><h3>Conclusions</h3><p>The study confirmed the effectiveness of Sidr honey against the tested multidrug-resistant pathogens. Additionally, our observations shed the light on the main secondary constituents in Yemini Sidr honey extracts, and their effective role in multidrug-resistant pathogens growth inhibition.</p></div>","PeriodicalId":577,"journal":{"name":"Future Journal of Pharmaceutical Sciences","volume":"11 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://fjps.springeropen.com/counter/pdf/10.1186/s43094-025-00774-x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143404245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sofosbuvir’s hepatoprotective efficacy in rats is enhanced by encapsulating in taurocholate-stabilized galactose-anchored bilosomes","authors":"Marwa Khaled Mohsen,&nbsp;Soheir Abo El azm Diab,&nbsp;Amani N. Shafik,&nbsp;Ahmed H. Osman,&nbsp;Marianne J. Naguib,&nbsp;Amira M. Kamel,&nbsp;Marwa Nagi Mehesen","doi":"10.1186/s43094-025-00775-w","DOIUrl":"10.1186/s43094-025-00775-w","url":null,"abstract":"<div><h3>Background</h3><p>In conjunction with other antiviral medicines, sofosbuvir (SOF) is an essential therapy for chronic hepatitis C. There is some debate over its influence on hepatic fibrosis. The use of nanotechnology in treatment has gained popularity, with the goal of delivering therapeutic substances to the liver to increase efficacy and decrease adverse effects. The aim of this study was to demonstrate the protective effect of sofosbuvir and the efficacy of incorporating nanoparticle galactosylated taurocholate bilosomal formula to SOF on thioacetamide-induced liver fibrosis.</p><h3>Methods</h3><p>Rats were divided into 7 groups: normal control, SOF, SOF encapsulated in galactosylated taurocholate bilosomal formula (nano-SOF), galactosylated taurocholate bilosomal formula (nanoparticle), thioacetamide (TAA), TAA-SOF and TAA-nano-SOF. Liver fibrosis was induced by TAA (200 mg/kg) intraperitoneal injection twice per week for 8 weeks. SOF, nanoparticle and nano-SOF were given (40 mg/Kg/day) orally from day one of the study. Serum activities of aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP) and tissue transforming growth factor beta (TGF-<i>β</i>) were assessed. Also, histopathological assessment of hepatic tissue was done.</p><h3>Results</h3><p>Administration of SOF and TAA to normal rats resulted in significant increase in serum AST, ALT, ALP and tissue TGF-β₁ levels with variable degree of liver fibrosis. Additionally, rats in TAA group that received SOF therapy did not exhibit improved liver functions, TGF-β₁ level and liver fibrosis score. However, administering nano-sofosbuvir prophylactically to TAA-treated rats resulted in a considerable improvement in liver function tests, TGF-1 levels, with liver fibrosis score regression.</p><h3>Conclusion</h3><p>In contrast to free sofosbuvir, SOF encapsulated in galactosylated taurocholate bilosomal formula (nano-SOF) displayed hepatoprotective effects in rat with thioacetamide-induced hepatic fibrosis. These findings strongly support the concept that galactoylatedbilosomes are promising nanocarrier for the targeted delivery of sofosbuvir to the liver.</p></div>","PeriodicalId":577,"journal":{"name":"Future Journal of Pharmaceutical Sciences","volume":"11 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://fjps.springeropen.com/counter/pdf/10.1186/s43094-025-00775-w","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143396568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Freeze-dried herbal Kaempferia galanga supplementation effectively modulates hyperglycemia-induced oxidative stress and apoptosis in diabetic BALB/c mice","authors":"Flavius Phrangsngi Nonglang,&nbsp;Revelbornstar Snaitang,&nbsp;Dhritiman Roy,&nbsp;Surya Bhan","doi":"10.1186/s43094-025-00772-z","DOIUrl":"10.1186/s43094-025-00772-z","url":null,"abstract":"<div><h3>Background</h3><p>A dysfunction in insulin secretion or action leads to hyperglycemia. Hyperglycemia then causes the activation of pathways that result in increased production of reactive oxygen and nitrogen species (ROS/RNS) levels, ultimately causing oxidative stress. Oxidative stress overload then causes cellular damage and also promotes the increased activation of the apoptosis pathway inducing cell death. Thus, regulation of glucose homeostasis to prevent hyperglycemia is crucial. In this study, the potential protective effect of <i>Kaempferia galanga</i> herbal extract (KGE) on hyperglycemia-induced oxidative stress and apoptosis was investigated.</p><h3>Result</h3><p>In this study, <i>Kaempferia galanga</i> (KG) herbal extracts, namely aqueous (KGA), ethanolic (KGE), methanolic (KGM), and chloroform (KGC), were tested for their antioxidant activity. In <i>in vitro</i> antioxidant assays, KG ethanolic extract (KGE) has the highest antioxidant activity out of all the extracts. High-performance thin layer chromatography phytochemical fingerprinting (HPTLC) analysis confirms that the presence of more antioxidant compounds in herbal KGE and ethyl-p methoxy cinnamate (EPMC) was the active phytochemical. Thus, KGE was chosen for <i>in vivo</i> studies. An intraperitoneal streptozotocin (STZ) administration produced a diabetic mouse model. <i>In vivo</i> herbal KGE treatment positively modulates SOD and CAT gene and protein expression in diabetic mice. Tissue protection from herbal KGE supplementation is supported by liver electron microscopy. In diabetic mice, herbal KGE supplementation reduces DNA fragmentation in the liver, kidney, pancreas, and heart by upregulating the gene and protein expression of anti-apoptotic BCL-2, inhibiting BAX expression, and ultimately inhibiting caspase-3 (CAS-3) expression. Herbal KGE supplementation in diabetic mice maintains insulin levels in serum and pancreas, indicating its protective role in preventing pancreatic damage or promoting β cell regeneration. Molecular docking analysis shows EPMC's high binding affinity for CAS-3, BAX, and BCL-2 compared to metformin suggesting that it may be responsible for modulating apoptotic protein expression.</p><h3>Discussion</h3><p>Herbal KGE supplementation protects against diabetes-induced tissue damage and apoptosis by reducing hyperglycemia-induced oxidative stress and apoptosis, and EPMC may be the active component eliciting the effect.</p></div>","PeriodicalId":577,"journal":{"name":"Future Journal of Pharmaceutical Sciences","volume":"11 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://fjps.springeropen.com/counter/pdf/10.1186/s43094-025-00772-z","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143396732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Detection, isolation, characterization, analytical method development with validation and in-silico analysis of new impurity in rivaroxaban","authors":"Manohar Reddy Epuru,&nbsp;Jagadam Saroja,&nbsp;Veera Venkata Nanda Kishore Pilli,&nbsp;Ravinder Reddy Vennapureddy","doi":"10.1186/s43094-025-00763-0","DOIUrl":"10.1186/s43094-025-00763-0","url":null,"abstract":"<div><h3>Background</h3><p>For rivaroxaban (RRBN) to be safe and effective, its quality and impurities need to be evaluated. One new impurity (IMP-20.15/2.57) was found during the analysis of intermediate stage compound of RRBN production. The isolation of IMP-20.15/2.57 was achieved by preparative HPLC, using 10 mM ammonium acetate and acetonitrile (gradient elution mode) as mobile phase. The IMP-20.15/2.57 was elucidated using mass spectrometer, FT-IR and NMR (¹H and ¹³C) techniques. A gradient RP-HPLC method was developed for IMP-20.15/2.57 quantification in RRBN API. The chromatographic separation of IMP-20.15/2.57 was done on a Zorbax Eclipse XDB [C18 3.0 mm × 15 cm, 3.5 µm] column with UV detection programmed at 250 nm. Solution A (methanol and buffer have been blended in a 05:95 v/v ratio) and Solution B (acetonitrile) make up the gradient mobile phase. The three batches of RRBN API were analyzed with the developed gradient RP-HPLC approach for the content of IMP-20.15/2.57. Risk assessment tests for IMP-20.15/2.57 were conducted utilizing in silico programs.</p><h3>Results</h3><p>The IMP-20.15/2.57 was elucidated as 4-(4-(2-hydroxy-3-(2-hydroxy-3-(4-(3-oxomorpholino) phenyl amino) propyl amino) propyl amino) phenyl) morpholin-3-one using mass spectrometer, FT-IR and NMR (¹H and ¹³C) techniques. The novel approach was evaluated in accordance with ICH requirements for linearity (0.2495–1.4971 µg/mL; R²-0.99958), accuracy (109.97–117.71% recovery), precision (0.6015–0.9211%RSD), specificity (996.5 peak purity), robustness (no significant variation in retention time and resolution), and quantification limitations (0.2495 µg/mL). The results were deemed appropriate. It became apparent that the IMP-20.15/2.57 content in three batches of RRBN API were below the quantification limits. The <i>in-silico</i> program suggested that there was certainly no possibility of mutagenicity with IMP-20.15/2.57.</p><h3>Conclusion</h3><p>The present gradient RP-HPLC approach suits best for the IMP-20.15/2.57 quantification in RRBN API and offers more effective ways to guarantee the safety of patients and the quality of RRBN.</p></div>","PeriodicalId":577,"journal":{"name":"Future Journal of Pharmaceutical Sciences","volume":"11 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://fjps.springeropen.com/counter/pdf/10.1186/s43094-025-00763-0","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143373248","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety profiles of IDH inhibitors: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database","authors":"Ximu Sun,&nbsp;Han Zhou,&nbsp;Yanming Li,&nbsp;Yanhui Luo,&nbsp;Qixiang Guo,&nbsp;Yixin Sun,&nbsp;Chenguang Jia,&nbsp;Bin Wang,&nbsp;Maoquan Qin,&nbsp;Peng Guo","doi":"10.1186/s43094-025-00769-8","DOIUrl":"10.1186/s43094-025-00769-8","url":null,"abstract":"<div><h3>Background</h3><p>With the increased use of isocitrate dehydrogenase (IDH) inhibitors in acute myeloid leukemia (AML) and cholangiocarcinoma, the toxicity of these drugs is a growing concern. This study aimed to evaluate the adverse events (AEs) of IDH inhibitors based on the Food and Drug Administration Adverse Event Reporting System (FAERS) database.</p><h3>Methods</h3><p>AE reports for IDH inhibitors (enasidenib, ivosidenib, and olutasidenib) were collected and analyzed from the time of launch through the first quarter of 2024. Only IDH inhibitors reported as the target drug and coded as the primary suspect (PS) were included in the analysis. AEs were standardized and classified according to the preferred term (PT) and system organ classification (SOC) in the Medical Dictionary for Regulatory Activities (MedDRA) version 26.0. Disproportionality analyses including the reporting odds ratio and the Bayesian confidence propagation neural network were performed in data mining to assess IDH inhibitor-relatedAEs. Differentiation syndrome was the AE of special interest.</p><h3>Results</h3><p>The reports number of enasidenib, ivosidenib, and olutasidenib was 11 616 357, 10 067 250, and 2 563 464, respectively. A total of 80 enasidenib-related signals involving 15 SOCs, 78 ivosidenib-related signals involving 17 SOCs, and 7 olutasidenib-related signals involving 4 SOCs were obtained. The most signals reported were “blood and lymphatic system disorders,” “infections and infestations,” and “nervous system disorders” in enasidenib. For signals of ivosidenib, the most frequently reported were “gastrointestinal disorders,” “general disorders and administration site conditions,” and “injury, poisoning and procedural complications.” Ivosidenib was the only IDH inhibitor with signals in “cardiac disorders.” Differentiation syndrome events were reported in 89, 40, and 2 cases for enasidenib, ivosidenib, and olutasidenib, respectively. The median time to onset was 26–31 days for ivosidenib and enasidenib. AML was the most common indication in the differentiation syndrome reports.</p><h3>Conclusions</h3><p>Our study identifies potential AE signals associated with IDH inhibitors and provides a broader understanding of the safety. The safety profiles highlight the need for long-term safety monitoring of IDH inhibitor recipients. Promptly monitoring and intervention in specific organ systems depending on the type of IDH inhibitor may improve the overall survival or enhance the quality of life. In the future, it will be necessary to validate our findings in prospective large-scale studies and to investigate the underlying mechanisms.</p></div>","PeriodicalId":577,"journal":{"name":"Future Journal of Pharmaceutical Sciences","volume":"11 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://fjps.springeropen.com/counter/pdf/10.1186/s43094-025-00769-8","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143361603","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}